FLASHDOSE Trademark

Trademark Overview

On Friday, January 7, 2005, a trademark application was filed for FLASHDOSE with the United States Patent and Trademark Office. The USPTO has given the FLASHDOSE trademark a serial number of 78543928. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, August 24, 2009. This trademark is owned by Biovail Laboratories, Inc.. The FLASHDOSE trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations and substances for the prevention, treatment and alleviation of stress; pharmaceutical preparations and substances for the prevention, treatment and alleviation of diabetes; pharmaceutical preparations and substances for controlling insulin levels; pharmaceutical preparations and substances for the prevention, treatment and alleviation of hypertension; pharmaceutical preparations and substances for the prevention, treatment and alleviation of angina; pharmaceutical preparations and substances for the cessation of smoking; pharmaceutical preparations and substances for the prevention and treatment of sexually transmitted diseases; pharmaceutical preparations and substances for the prevention and treatment of herpes; pharmaceutical preparations and substances for the prevention, treatment and alleviation of disorders, diseases, conditions and ailments of the central nervous system; pharmaceutical preparations and substances for the prevention, treatment and al...
flashdose

General Information

Serial Number78543928
Word MarkFLASHDOSE
Filing DateFriday, January 7, 2005
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, August 24, 2009
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, May 2, 2006

Trademark Statements

Goods and ServicesPharmaceutical preparations and substances for the prevention, treatment and alleviation of stress; pharmaceutical preparations and substances for the prevention, treatment and alleviation of diabetes; pharmaceutical preparations and substances for controlling insulin levels; pharmaceutical preparations and substances for the prevention, treatment and alleviation of hypertension; pharmaceutical preparations and substances for the prevention, treatment and alleviation of angina; pharmaceutical preparations and substances for the cessation of smoking; pharmaceutical preparations and substances for the prevention and treatment of sexually transmitted diseases; pharmaceutical preparations and substances for the prevention and treatment of herpes; pharmaceutical preparations and substances for the prevention, treatment and alleviation of disorders, diseases, conditions and ailments of the central nervous system; pharmaceutical preparations and substances for the prevention, treatment and alleviation of depression; anti-depressants; pharmaceutical preparations and substances for the prevention, treatment and alleviation of sleep disorders; pharmaceutical preparations and substances for the prevention, treatment and alleviation of anxiety; pharmaceutical preparations and substances for the prevention, treatment and alleviation of disorders, diseases, conditions and ailments of the cardio-vascular system; pharmaceutical preparations and substances for the prevention, treatment and alleviation of acute myocardial infarctions; pharmaceutical preparations and substances for the prevention, treatment and alleviation of symptomatic congestive heart failure; pharmaceutical preparations and substances for the prevention, treatment and alleviation of asymptomatic left ventricular dysfunction; pharmaceutical preparations and substances, namely, fibrinolytic or thrombolytic agents; pharmaceutical preparations and substances for the prevention, treatment and alleviation of disorders, diseases, conditions and ailments of the respiratory system; pharmaceutical preparations and substances for the prevention, treatment and alleviation of disorders, diseases, conditions and ailments of the endocrine system; pharmaceutical preparations and substances for the prevention, treatment and alleviation of disorders, diseases, conditions and ailments of the immune system; pharmaceutical preparations and substances for the prevention, treatment and alleviation of disorders, diseases, conditions and ailments of the musculo-skeletal system, namely, bone diseases and bone degenerative conditions; pharmaceutical preparations and substances for the prevention, treatment and alleviation of pain and inflammation, namely, pain relief medication and anti-inflammatories; pharmaceutical preparations and substances for the prevention, treatment and alleviation of migraines; pharmaceutical preparations and substances, namely, medicated skin care preparations for use in dermatology, namely, dermatitis and skin pigmentation diseases; pharmaceutical preparations and substances for use in oncology; pharmaceutical preparations and substances for use in ophthalmology; pharmaceutical preparations and substances for the treatment of polycystic ovary syndrome; pharmaceutical preparations and substances for the treatment of infertility; pharmaceutical preparations and substances for the prevention, treatment and alleviation circulatory, neurologic, alimentary, auto-immune, pulmonary, musculoskeletal, lymphatic, gastrointestinal, bone sensory, viral, urinary, renal, infectious or metabolic diseases, illnesses, disorders or conditions; metformin; diltiazem; tramadol; carvedilol; bupropion; metoprolol; citalopram; zolpidem; fluoxetine; venlafaxine; lorazepam; and sumatriptan
Pseudo MarkFLASH DOSE

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateWednesday, January 19, 2005
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameBIOVAIL LABORATORIES INTERNATIONAL SRL
Party Type21 - New Owner After Publication
Legal Entity Type99 - Other
AddressChrist Church BB17154
BB
Party NameBiovail Laboratories, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressCollymore, St. Michael
BB
Party NameBiovail Laboratories, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressCollymore, St. Michael
BB

Trademark Events

Event DateEvent Description
Wednesday, October 13, 2010ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
Monday, August 24, 2009ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILED
Monday, August 24, 2009ABANDONMENT - NO USE STATEMENT FILED
Wednesday, June 17, 2009ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
Thursday, February 5, 2009EXTENSION 5 GRANTED
Thursday, January 22, 2009EXTENSION 5 FILED
Thursday, February 5, 2009CASE ASSIGNED TO INTENT TO USE PARALEGAL
Thursday, January 22, 2009TEAS EXTENSION RECEIVED
Thursday, January 22, 2009APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Thursday, January 22, 2009TEAS CHANGE OF OWNER ADDRESS RECEIVED
Thursday, July 17, 2008EXTENSION 4 GRANTED
Thursday, July 17, 2008EXTENSION 4 FILED
Thursday, July 17, 2008TEAS EXTENSION RECEIVED
Thursday, February 7, 2008EXTENSION 3 GRANTED
Friday, January 18, 2008EXTENSION 3 FILED
Friday, January 18, 2008TEAS EXTENSION RECEIVED
Saturday, September 29, 2007TEAS CHANGE OF CORRESPONDENCE RECEIVED
Friday, September 14, 2007EXTENSION 2 GRANTED
Thursday, July 12, 2007EXTENSION 2 FILED
Thursday, July 12, 2007TEAS EXTENSION RECEIVED
Wednesday, December 27, 2006EXTENSION 1 GRANTED
Thursday, November 9, 2006EXTENSION 1 FILED
Thursday, November 9, 2006TEAS EXTENSION RECEIVED
Tuesday, July 25, 2006NOA MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, May 2, 2006PUBLISHED FOR OPPOSITION
Wednesday, April 12, 2006NOTICE OF PUBLICATION
Tuesday, March 14, 2006LAW OFFICE PUBLICATION REVIEW COMPLETED
Friday, March 10, 2006ASSIGNED TO LIE
Wednesday, March 8, 2006APPROVED FOR PUB - PRINCIPAL REGISTER
Friday, March 3, 2006TEAS/EMAIL CORRESPONDENCE ENTERED
Thursday, February 9, 2006CORRESPONDENCE RECEIVED IN LAW OFFICE
Thursday, February 9, 2006TEAS RESPONSE TO OFFICE ACTION RECEIVED
Tuesday, August 9, 2005NON-FINAL ACTION E-MAILED
Tuesday, August 9, 2005NON-FINAL ACTION WRITTEN
Tuesday, August 9, 2005ASSIGNED TO EXAMINER
Wednesday, April 13, 2005TEAS CHANGE OF CORRESPONDENCE RECEIVED
Wednesday, January 19, 2005NEW APPLICATION ENTERED IN TRAM

Related Keywords

flashdose substances preparations pharmaceutical treatment prevention alleviation diseases disorders conditions herpes